<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492387</url>
  </required_header>
  <id_info>
    <org_study_id>DURATION</org_study_id>
    <nct_id>NCT01492387</nct_id>
  </id_info>
  <brief_title>Duration of Antibiotic Therapy in Community - Acquired Pneumonia</brief_title>
  <acronym>DURATION</acronym>
  <official_title>Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of an individualized approach to duration
      of antibiotic therapy based on each subject's clinical response compared to a local standard
      approach in patients coming from the community and who are hospitalized because of a
      pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome including adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Any among the following: 1) disease-specific complications due to pneumonia, such as lung abscess, empyema, meningitis, endocarditis, arthritis or pericarditis; 2) clinical failure during hospitalization (either hemodynamic or respiratory failure); 3) a new course of antibiotics (at least one dose), after discontinuation of antibiotic therapy given for the pneumonia, either endovenous or oral; 4) re-hospitalization; 5) death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite outcome of other adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Any among the following: 1) disease-specific complications due to pneumonia, such as lung abscess, empyema, meningitis, endocarditis, arthritis or pericarditis; 2) clinical failure due to pneumonia occurring during hospitalization (either hemodynamic or respiratory failure); 3) a new course of antibiotics (at least one dose), after discontinuation of antibiotic therapy given for the pneumonia, either endovenous or oral, for a relapse of pneumonia; 4) re-hospitalization due to a relapse of pneumonia; 5) death due to pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic exposure</measure>
    <time_frame>90 days</time_frame>
    <description>Days of antibiotic exposure, including intravenous and oral antibiotic therapy given for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse effects will include: anaphylactic reactions and allergic skin reactions; Clostridium difficile-associated colitis; hematologic toxicity; hepatotoxicity; convulsions; tendinopathies; peripheral neuropathy; prolongation of the QTc interval; nausea; diarrhea; vomiting; abdominal pain; nephrotoxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome of other adverse events at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Any among the following: 1) a new course of antibiotics for any reason after discontinuation of antibiotic therapy for pneumonia; 2) re-hospitalization for any reason; 3) death from any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days from the date of admission to the hospital to either the date of discharge (patients sent home or to a long-term care facility) or the date of death if occurred during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>30 days</time_frame>
    <description>Costs of care differences between the two study groups based on the total length of hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">892</enrollment>
  <condition>Pneumonia</condition>
  <condition>Bronchopneumonia</condition>
  <condition>Pleuropneumonia</condition>
  <condition>Pneumonia, Bacterial</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Local standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individualized arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discontinuation of antibiotic therapy</intervention_name>
    <description>Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.</description>
    <arm_group_label>Individualized arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be 18 years old or older and meet all of the following inclusion criteria to
        be eligible for enrollment into the trial:

          1. Diagnosis of pneumonia:

             Evidence of a new pulmonary infiltrate seen on either radiograph or computed
             tomography of the chest within 48 hours after hospitalization plus at least two among
             the following: 1) new or increased cough with/without sputum production and/or
             purulent respiratory secretions; 2) fever (documented temperature -rectal or oral- ≥
             37.8 °C) or hypothermia (documented temperature -rectal or oral- &lt;36o C); 3)
             deterioration of oxygenation; 4) evidence of systemic inflammation (such as abnormal
             white blood cell count -either leukocytosis (&gt;10,000/cm3) or leukopenia (&lt; 4,000/cm3)
             - or increasing of C-reactive protein or procalcitonin values above the local upper
             limit.

             CAP will be defined as pneumonia occurring in any patient admitted to the hospital
             coming from the community and who were not hospitalized in the previous 14 days. HCAP
             will be defined as a community-acquired pneumonia occurring in a patient with any of
             the following special epidemiological characteristics: patient who was hospitalized
             for 2 days or more in the previous 90 days; patient coming from a nursing home or
             extended care facility; patient who received home infusion therapy (including
             antibiotics) or wound care in the previous 30 days; patient who was on chronic
             dialysis in the previous 30 days.

          2. An appropriate empiric antibiotic therapy for the pneumonia received within 24 hours
             after admission to the hospital.

          3. A clinical stability reached within 5 days after hospital admission, in the absence of
             any changes of the initial empiric antibiotic therapy.

          4. Signed informed consent

        Exclusion Criteria:

        Patients presenting with any of the following will not be included in the trial:

          1. Patients with immunodeficiency, defined as: chemotherapy in the previous 12 months,
             radiotherapy in the previous 12 months, transplantation, immunosuppressive treatment,
             hematologic malignancy, AIDS or HIV with CD4 count &lt; 200, asplenia.

          2. Patients with a concomitant infection on admission to the hospital requiring
             antibiotic therapy (i.e urinary tract infection). The presence of sepsis due to
             pneumonia will not be considered another concomitant infection.

          3. Patients with documented bacteremia due to S. aureus in a blood culture (both
             methicillin resistant and susceptible S. aureus)

          4. Patients with etiology of pneumonia due to fungi, mycobacterium or Pneumocystis
             jiroveci.

          5. Patients hospitalized in the previous 15 days

        Inclusion and exclusion criteria for the proposed study will not limit the study cohort on
        the basis of sex, ethnicity, socioeconomic status or other potentially discriminatory
        factors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Aliberti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milano Bicocca, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio A Ramirez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville, KY, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Aliberti, MD</last_name>
    <phone>00393394171538</phone>
    <email>stefano.aliberti@unimib.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Blasi, MD</last_name>
    <email>francesco.blasi@unimi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Michetti, MD</last_name>
      <email>gmichetti@ospedaliriuniti.bergamo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Policlinico S. Orsola Malpighi, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Viale, MD</last_name>
      <email>pierluigi.viale@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Nava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO S. Anna</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Rosa Maspero, MD</last_name>
      <email>anna.maspero@hsacomo.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Genoa</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Viscoli, MD</last_name>
      <email>claudio.viscoli@unige.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO C. Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Sturani, MD</last_name>
      <email>carlo.sturani@aopoma.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO San Carlo Borromeo</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Amaducci, MD</last_name>
      <email>amaducci.sandro@sancarlo.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Blasi, MD</last_name>
      <email>francesco.blasi@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Cosentini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco, University of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Montano, MD</last_name>
      <email>nicola.montano@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Franzetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Richeldi, MD</last_name>
      <email>luca.richeldi@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univeristy of Milano Bicocca</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Aliberti, MD</last_name>
      <email>stefano.aliberti@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Aliberti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Gori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo, University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Luisetti, MD</last_name>
      <email>m.luisetti@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Zucchi, MD</last_name>
      <email>zucchi.luigi@asmn.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Voza, MD</last_name>
      <email>antonio.voza@humanitas.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico di San Donato Milanese, University of Milan</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Valenti, MD</last_name>
      <email>vincenzo.valenti@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO S. Maria della Misericordia,</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Rossi, MD</last_name>
      <email>rossi.paolo@aoud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Matteo Bassetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.caposite.com</url>
  </link>
  <reference>
    <citation>Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S, Ramirez JA. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2010 Jul;36(1):128-34. doi: 10.1183/09031936.00130909. Epub 2009 Nov 19.</citation>
    <PMID>19926738</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.</citation>
    <PMID>17278083</PMID>
  </reference>
  <reference>
    <citation>Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011 Nov;17 Suppl 6:E1-59. doi: 10.1111/j.1469-0691.2011.03672.x.</citation>
    <PMID>21951385</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Francesco Blasi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>community-acquired pneumonia</keyword>
  <keyword>healthcare-associated pneumonia</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>Duration of therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pleuropneumonia</mesh_term>
    <mesh_term>Bronchopneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

